Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2025 19:40 ET | Source: Curium US LLC

キュリウム (Curium)、ルテチウム177の供給能力およびPET分野の事業拡大計画の一環としてモンロール (Monrol) の買収を完了

キュリウムは、ルテチウム177アイソトープの主要製造企業としての地位を確立革新的な研究開発の専門性および開発パイプラインをキュリウムにもたらすSPECTおよびPETにおけるキュリウムの地理的展開とサプライチェーンを強化パリ発, March 29, 2025 (GLOBE NEWSWIRE) -- 核医学の世界的リーダーであるキュリウム・ファーマ (Curium Pharma)...
March 28, 2025 19:40 ET | Source: Curium US LLC

Curium משלימה את רכישת Monrol כחלק מהתוכנית שלה להרחיב משמעותית את הקיבולת של לוטיציום-177 וטביעת הרגל של השימוש ב-PET

*תמצב את Curium כיצרנית מובילה של איזוטופ לוטיציום-177 *מביאה מומחיות מו"פ חדשנית וצנרת ייצור ל-Curium *משפרת את הכיסוי הגיאוגרפי ואת שרשרת האספקה של עבור ה-SPECT & PET של Curium פריז, March ...
March 28, 2025 19:40 ET | Source: Curium US LLC

Curium finalise l’acquisition de Monrol, axée sur le net renforcement de sa capacité de production de lutécium-177 et de son empreinte PET

Affirmation de son leadership dans la production de l’isotope lutétium-177Renforcement de son expertise en R&D et consolidation de son pipeline innovantExtension de sa couverture géographique et...
March 28, 2025 02:00 ET | Source: Curium

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium
January 30, 2025 07:22 ET | Source: Curium

Curium Expands European Supply of Iodine-131 Diagnostic Capsules with New Partnership Agreement with Izotop

Curium announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop).
January 28, 2025 04:24 ET | Source: Curium

Curium Further Expands European Availability of PYLCLARI – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients with Prostate Cancer

Curium announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer.
November 19, 2024 03:30 ET | Source: Curium

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

ST. LOUIS, Mo., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that it has completed enrollment of its Phase 3 SOLAR-RECUR clinical trial. The trial is a...
November 13, 2024 10:57 ET | Source: Curium

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center,...
October 02, 2024 11:01 ET | Source: Curium US LLC

핵의학 기업 Curium, 일본의 전립선암 테라노스틱 분야 공동 개발 위해 PeptiDream과 전략적 파트너십 체결

177Lu-PSMA-I&T 및 64Cu-PSMA-I&T 의 일본 내 임상 개발, 규제 신청 및 상용화 추진 과정에서의 협력 포함양사 간 오랜 기간 형성된 관계를 바탕으로 파트너십 구축일본의 전립선암 신규 진단건수 매년 약 9만 건 수준 파리, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 핵의학 부문을 선도하는...
October 02, 2024 11:01 ET | Source: Curium US LLC

Curium 宣布與 PeptiDream 建立策略夥伴關係，在日本前列腺癌治療學領域展開合作

合作內容包括 177Lu-PSMA-I&T 和 64Cu-PSMA-I&T 在日本的臨床開發、監管備案和商業化工作基於兩間公司的長期合作關係日本每年有大約 9 萬宗前列腺癌新病例確診巴黎, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Curium 是一家世界領先的核醫學企業，今天宣布與 PeptiDream 的全資子公司...